FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107872222> ?p ?o ?g. }

• W2107872222 endingPage "S53" @default.
• W2107872222 startingPage "S41" @default.
• W2107872222 abstract "Disease-modifying therapies (DMTs) are a core component of multiple sclerosis (MS) management. Given current constraints on health care expenditures, the relative cost-effectiveness of these therapies needs to be considered when making treatment decisions. The objective of this article is to review the burden of illness of MS, discuss the cost-effectiveness data for DMTs, and summarize the implications for payers. For the burden of illness in MS, a retrospective analysis of managed care administrative data from the IMS LifeLink Health Plan Claims Database was performed. Data from claims submitted for patients with confirmed MS (ICD-9-CM code 340) over a period of 1 year (2009) were analyzed. A literature review was conducted to put these data into perspective. The retrospective analysis determined that the mean annual cost of treating MS in the United States in 2009 was $23,434, which varied according to the presence of comorbidities/complications. Overall, DMTs accounted for 69% of the total costs of managing the disease. According to the literature review, the typical first-line DMTs (interferon beta [IFNβ] formulations and glatiramer acetate [GA]) are generally associated with incremental cost-utility or cost-effectiveness ratios in excess of $100,000 per quality of life year gained. Natalizumab may have cost benefits over other agents in patients with more aggressive disease. According to the available data, studies indicate that DMT cost-effectiveness (specifically cost per quality-adjusted life years) appears to improve with treatment initiation during the early stages of the disease. In relapsing-remitting MS, there is currently little evidence to differentiate between the DMTs that are typically used first-line (IFNs and GA) based on cost-effectiveness or cost-utility studies. Presently, optimal therapy decisions for DMT-naïve patients are likely to be made individually based on patient and provider preference, adherence, and medication risk-benefit profiles. For patients with more advanced disease, natalizumab appears to have greater efficacy and to be more cost-effective than other agents." @default.
• W2107872222 created "2016-06-24" @default.
• W2107872222 creator A5027030300 @default.
• W2107872222 creator A5031741849 @default.
• W2107872222 creator A5048587737 @default.
• W2107872222 creator A5051028825 @default.
• W2107872222 date "2013-01-01" @default.
• W2107872222 modified "2023-09-26" @default.
• W2107872222 title "Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies" @default.
• W2107872222 cites W110791873 @default.
• W2107872222 cites W129862459 @default.
• W2107872222 cites W146365059 @default.
• W2107872222 cites W1649122414 @default.
• W2107872222 cites W1967311612 @default.
• W2107872222 cites W1970101726 @default.
• W2107872222 cites W1970213344 @default.
• W2107872222 cites W1970693461 @default.
• W2107872222 cites W1970963099 @default.
• W2107872222 cites W1973256647 @default.
• W2107872222 cites W1983115602 @default.
• W2107872222 cites W1997577436 @default.
• W2107872222 cites W1997817922 @default.
• W2107872222 cites W2001446148 @default.
• W2107872222 cites W2004286309 @default.
• W2107872222 cites W2010121852 @default.
• W2107872222 cites W2011795781 @default.
• W2107872222 cites W2014945831 @default.
• W2107872222 cites W2025790867 @default.
• W2107872222 cites W2030592068 @default.
• W2107872222 cites W2036150740 @default.
• W2107872222 cites W2042365691 @default.
• W2107872222 cites W2042625847 @default.
• W2107872222 cites W2042906937 @default.
• W2107872222 cites W2043044514 @default.
• W2107872222 cites W2045920400 @default.
• W2107872222 cites W2046655585 @default.
• W2107872222 cites W2046712471 @default.
• W2107872222 cites W2053199643 @default.
• W2107872222 cites W2073321077 @default.
• W2107872222 cites W2074098853 @default.
• W2107872222 cites W2075033945 @default.
• W2107872222 cites W2078501053 @default.
• W2107872222 cites W2078513771 @default.
• W2107872222 cites W2082727602 @default.
• W2107872222 cites W2088546205 @default.
• W2107872222 cites W2089126944 @default.
• W2107872222 cites W2095666175 @default.
• W2107872222 cites W2101000495 @default.
• W2107872222 cites W2103807545 @default.
• W2107872222 cites W2109323249 @default.
• W2107872222 cites W2112270506 @default.
• W2107872222 cites W2123038985 @default.
• W2107872222 cites W2129615089 @default.
• W2107872222 cites W2130779793 @default.
• W2107872222 cites W2133906017 @default.
• W2107872222 cites W2134015462 @default.
• W2107872222 cites W2136981251 @default.
• W2107872222 cites W2139255064 @default.
• W2107872222 cites W2139855695 @default.
• W2107872222 cites W2141185335 @default.
• W2107872222 cites W2141919552 @default.
• W2107872222 cites W2144095014 @default.
• W2107872222 cites W2145552726 @default.
• W2107872222 cites W2148563799 @default.
• W2107872222 cites W2153143281 @default.
• W2107872222 cites W2154141200 @default.
• W2107872222 cites W2161906602 @default.
• W2107872222 cites W2165775694 @default.
• W2107872222 cites W2167124391 @default.
• W2107872222 cites W2169309931 @default.
• W2107872222 cites W2188468660 @default.
• W2107872222 cites W2168709334 @default.
• W2107872222 cites W2440310590 @default.
• W2107872222 cites W2544544554 @default.
• W2107872222 cites W29885708 @default.
• W2107872222 doi "https://doi.org/10.18553/jmcp.2013.19.s1.s41" @default.
• W2107872222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23383732" @default.
• W2107872222 hasPublicationYear "2013" @default.
• W2107872222 type Work @default.
• W2107872222 sameAs 2107872222 @default.
• W2107872222 citedByCount "40" @default.
• W2107872222 countsByYear W21078722222013 @default.
• W2107872222 countsByYear W21078722222014 @default.
• W2107872222 countsByYear W21078722222015 @default.
• W2107872222 countsByYear W21078722222016 @default.
• W2107872222 countsByYear W21078722222017 @default.
• W2107872222 countsByYear W21078722222018 @default.
• W2107872222 countsByYear W21078722222019 @default.
• W2107872222 countsByYear W21078722222020 @default.
• W2107872222 countsByYear W21078722222021 @default.
• W2107872222 countsByYear W21078722222022 @default.
• W2107872222 countsByYear W21078722222023 @default.
• W2107872222 crossrefType "journal-article" @default.
• W2107872222 hasAuthorship W2107872222A5027030300 @default.
• W2107872222 hasAuthorship W2107872222A5031741849 @default.
• W2107872222 hasAuthorship W2107872222A5048587737 @default.
• W2107872222 hasAuthorship W2107872222A5051028825 @default.
• W2107872222 hasBestOaLocation W21078722222 @default.

• next